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A b s t r a c t
Background: Studies published during the last decade seem to indicate red blood cell parameters as inexpensive, rapidly 
available, and simple tools for the assessment of prognosis in patients with chronic heart failure (CHF).
Aim: To evaluate the prognostic value of red cell parameters determined in a routine blood count in patients with CHF.
Methods: The study group included 165 patients with the New York Heart Association (NYHA) class II–IV CHF hospitalised in 
the 2nd Department of Cardiology in Bydgoszcz. On the first day of hospitalisation, all patients in the study group underwent 
a complete blood count with an assessment of haemoglobin (Hb) level, mean corpuscular volume (MCV), mean corpuscular 
haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) and red blood cell distribution width (RDW). 
Follow-up was carried over 24 months by phone calls every 3 months.
Results: MCV, MCH and MCHC were not shown to be significant predictors of mortality in CHF patients at 1 and 2 years of 
follow-up. In univariate analysis at 1-year follow-up, the following variables were significantly associated with the occurrence 
of the study endpoint: Hb level (p = 0.022; HR = 0.80), RDW (p = 0.004; HR = 1.257), and N-terminal pro-B-type na-
triuretic peptide (NT-proBNP) level (p = 0.0001; HR = 1). At 2 years of follow-up, the following variables were significantly 
associated with the occurrence of the study endpoint: left ventricular ejection fraction (p = 0.018; HR = 0.956), NYHA class 
(p = 0.007; HR = 0.378), RDW (p = 0.044; HR = 1.175), and NT-proBNP level (p < 0.001; HR = 1). Multivariate analysis 
for 1-year follow-up showed that RDW and NT-proBNP level were independent significant predictors of mortality, while 
NT-proBNP level (p = 0.006; HR = 1) and NYHA class (p = 0.024; HR = 0.439) were significant predictors of mortality at 
2 years of follow-up. Based on receiver operating characteristic curve analysis, the cut-off RDW was 15.00% (AUC = 0.63; 
0.523–0.737), at 12 months of follow-up and 14.00% (AUC = 0.6; 0.504–0.697), at 24 months of follow-up. The cut-off for 
Hb level was 13.9 g/dL (AUC = 0.662; 0.553–0.77), at 12 months of follow-up and 12.2 g/dL (AUC = 0.581; 0.482–0.681), 
at 24 months of follow-up.
Conclusions: Baseline RDW and Hb level in patients hospitalised with the diagnosis of NYHA class II–IV CHF seem to be 
important predictors of mortality in this population. Among the red blood cell parameters, only RDW was shown to be an 
independent prognostic factor at 1 year of follow-up but it appeared to lose its significance during longer-term follow-up.
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INTRODUCTION
Based on the POLKARD HF registry data, the number of 
patients with chronic heart failure (CHF) in Poland has been 
estimated at 500,000 to 750,000 [1, 2]. Mortality among 
these patients is 30–40% during 1 year since the diagnosis of 
CHF, and up to 70% at 5 years [3]. The very term “epidemic 
of heart failure”, as coined by Massie and Shah [4], suggests 
this condition is associated with a number of medical and 
economic problems, and if heart transplantation is needed, 
also religious and ethical issues. Thus, it is necessary to identify 
factors which have the greatest effect on the prognosis in this 
patient group. Studies published during the last decade seem 
to indicate red blood cell parameters as inexpensive, rapidly 
available, and simple prognostic tools, and determining their 
precise pathophysiological links to CHF may contribute to the 
development of new therapeutic options. The aim of the study 
was to evaluate the prognostic value of red cell parameters 
determined in a routine blood count in patients with systolic 
CHF who were followed for 24 months.
METHODS
The study group included 165 Caucasian patients with the 
New York Heart Association (NYHA) class II–IV systolic CHF 
who were hospitalised in the 2nd Department of Cardiology 
at the Nicolaus Copernicus University Collegium Medicum 
in Bydgoszcz, Poland. All patients included into the study 
were haemodynamically stable, did not require intravenous 
inotropic agents, and received optimal drug therapy. The 
patients were hospitalised on an elective basis to evaluate 
the severity of heart failure (HF) (cardiac catheterisation) or 
perform other diagnostic testing necessary before considering 
heart transplantation, cardioverter-defibrillator implantation, 
or cardiac resynchronisation therapy. The inclusion criteria 
were age above 18 years and systolic HF with left ventricular 
ejection fraction (LVEF) of < 45% documented during the 
index hospitalisation or within 6 months. The exclusion criteria 
included an acute coronary syndrome, acute HF, exacerba-
tion of CHF, severe renal dysfunction (GFR < 30 mL/min), 
active malignancy, active infection, fever of unknown origin, 
autoimmune diseases, corticosteroid therapy, decompensated 
diabetes requiring intravenous insulin infusion, chronic ob-
structive pulmonary disease, iron therapy, and chronic inflam-
matory bowel disease. In all patients, complete blood count 
was performed on the first day of hospitalisation, including 
haemoglobin (Hb) level, mean corpuscular volume (MCV), 
mean corpuscular haemoglobin (MCH), mean corpuscular 
haemoglobin concentration (MCHC), and red cell distribution 
width (RDW). In addition, iron, ferritin, N-terminal pro-B-type 
natriuretic peptide (NT-proBNP), troponin T (TnT), and choles-
terol fraction (LDL, HDL) levels were measured. Follow-up to 
evaluate endpoint occurrence was by phone every 3 months 
since patient inclusion into the study. Duration of follow-up 
was 24 months, and the study endpoint was all-cause mortality.
Statistical analysis
Results were analysed using the Statistica version 12 soft-
ware. For all tests, p < 0.05 was considered significant. 
Normal distribution of the evaluated variables was verified 
using the Shapiro-Wilk test. Non-parametric tests were used 
for non-normally distributed variables. Haemoglobin level, 
MCV, MCH, MCHC, and RDW were compared overall and 
in relation to the occurrence of death at 12 and 24 months 
of follow-up, using the Mann-Whitney U test. Evaluation of 
the diagnostic power of RDW, NT-proBNP level, and Hb level 
for predicting mortality during 12 and 24 months of follow-up 
was performed using receiver operating characteristic (ROC) 
curves. ROC curves were also used to determine cut-off levels 
of RDW and Hb. Relations between Hb, MCV, MCH, MCHC, 
RDW, NT-proBNP level, TnT level, and LVEF were evaluated 
using the Spearman ran correlation coefficients. Hazard 
ratios (HR) were calculated based univariate analyses and 
Cox multivariate analysis. Survival was evaluated using the 
Kaplan-Meier curves.
RESULTS
We evaluated 165 patients (83% men) at the mean age of 
60 ± 13 years. During 24 months of follow-up, 47 (28.5%) 
patients died. These cases were characterised by significantly 
lower LVEF, higher RDW, and higher TnT and NT-proBNP 
levels. Clinical and laboratory characteristics of the study 
group are shown in Table 1. Table 2 shows Spearman rank 
correlations in the study group.
In our study group, MCV, MCH and MCHC were not use-
ful predictors of mortality at 12 and 24 months of follow-up. 
In univariate analysis at 12 months of follow-up, summarised 
in Table 3, the following variables were significantly associ-
ated with the occurrence of the study endpoint: Hb level 
(p = 0.022; HR = 0.80), RDW (p = 0.004; HR = 1.257), 
and NT-proBNP level (p = 0.0001; HR = 1). In multivariate 
analysis, RDW and NT-proBNP level were independent, sig-
nificant predictors of mortality during 12 months of follow-up 
(Table 3).
Cox proportional hazard model univariate analysis for 
24 months of follow-up, summarised in Table 4, showed 
that the following variables were significantly associated with 
the occurrence of the study endpoint: LVEF (p = 0.018; 
HR = 0.956), NYHA class (p = 0.007; HR = 0.378), RDW 
(p = 0.044; HR = 1.175), and NT-proBNP level (p < 0.001; 
HR = 1). In multivariate analysis, NT-proBNP level (p = 0.006; 
HR = 1) and worse NYHA class (p = 0.024; HR = 0.439) 
were independent, significant predictors of mortality during 
24 months of follow-up (Table 4).
We analysed ROC curves for Hb level and RDW, com-
paring them the ROC curve for NT-proBNP level for 12 and 
24 months of follow-up and providing AUC and cut-off val-
ues for each of these predictors of prognosis. The cut-off for 
RDW was 15.00% (AUC = 0.63; 0.523–0.737) for 12 months 
www.kardiologiapolska.pl
Prognostic significance of red cell distribution width and other red cell parameters in patients with CHF 
659
Table 1. Baseline characteristics of the study groups
Parameter Overall (n = 165) Survivors (n = 118; 71.5%) Died (n = 47; 28.5%) P
Age [years] 60 ± 13 59 ± 13 61 ± 14 0.677
Men 83% 81% 89% 0.172
Ischaemic aetiology 53% 52% 57% 0.504
Body mass index [kg/m2] 29 ± 6 28 ± 6 30.00 ± 6 0.125
NYHA class II/III/IV 39.4%/50.9%/9.7% 46.6%/44.9%/8.5% 21.27%/66%/12.73% 0.011
Diabetes mellitus 36% 36% 38% 0.744
Left ventricular ejection fraction [%] 27 ± 8 28 ± 8 24 ± 8 0.007
Haemoglobin [g/dL] 14 (13.2–15) 14.1 (13.3–15.1) 13.8 (12–14.9) 0.104
MCV [fL] 90.3 (87.5–93.5) 90.3 (87–93.5) 90.4 (87.9–96.4) 0.654
MCH [pg] 30.3 (28.8–31.3) 30.3 (28.8–31.2) 30.3 (28.7–31.7) 0.836
MCHC [g/dL] 33.1 (32.5–34) 33.2 (32.5–33.9) 33 (32.5–34.1) 0.671
RDW [%] 13.9 (13.2–15) 13.8 (13.1–14.7) 14.2 (13.5–15.9) 0.044
Troponin T [µg/L] 0.02 (0.013–0.034) 0.02 (0.011–0.030) 0.03 (0.018–0.043) 0.001
NT-proBNP [pg/mL] 1862 (730–4088) 1308 (569–3491) 3224 (1156–4971) 0.001
Fe [µg/dL] 74 (53–100) 77.5 (54–104) 65 (51–83) 0.139
Ferritin [µg/dL] 141 (85–247) 141.5 (88–250) 139 (55–241) 0.901
Low density lipoprotein [mg/dL] 104 (80–134) 104 (88–133) 96 (81–138) 0.968
High density lipoprotein [mg/dL] 38 (31–48) 38.5 (32–47) 36 (30–49) 0.694
ACE inhibitor 82% 84% 77% 0.382
Angiotensin receptor blocker 18% 16% 23% 0.669
Statin 81% 82% 79% 0.767
Beta-blocker 99% 100% 98% 0.633
Acetylsalicylic acid 48% 47% 49% 0.999
Digoxin 27% 26% 28% 0.99
Spironolactone 74% 76% 68% 0.376
Eplerenone 18% 16% 23% 0.395
Results expressed as: mean values ± standard deviation or median values (interquartile range); ACE — angiotensin converting enzyme; MCH — 
mean corpuscular haemoglobin; MCHC — mean corpuscular haemoglobin concentration; MCV — mean corpuscular volume; NT-proBNP —  
N-terminal pro-B-type natriuretic peptide; NYHA — New York Heart Association; RDW — red blood cell distribution width
Table 2. Spearman rank correlations in the study population (n = 165); bold indicates statistically significant values (p < 0.05)
EF Haemoglobin RDW NT-proBNP Troponin T
EF 1 –0.115 –0.042 –0.345 –0.015
Haemoglobin –0.115 1 –0.218 –0.228 –0.122
MCV –0.037 0.135 –0.156 0.135 0.144
MCH –0.017 0.07 –0.351 –0.112 0.024
MCHC 0.031 0.012 –0.447 –0.421 –0.193
RDW –0.042 –0.218 1 0.319 0.097
Troponin T –0.015 –0.122 0.097 0.332 1
NT–proBNP –0.345 –0.228 0.319 1 0.332
EF — ejection fraction; rest abbreviation as in Table 1
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of follow-up and 14.00% (AUC = 0.6; 0.504–0.697) for 
24 months of follow-up (Figs. 1, 2).
For Hb level, the cut-off was 13.9 g/dL (AUC = 0.662; 
0.553–0.77) for 12 months of follow-up and 12.2 g/dL 
(AUC = 0.581; 0.482–0.681) (Figs. 3, 4).
For NT-proBNP level, the cut-off values for 12 and 
24 months of follow-up were 2943 pg/mL (AUC = 0.684; 
0.582–0.787) and 1615 pg/mL (AUC = 0.659; 0.569–0.75), 
respectively (Table 5).
These cut-off values were then applied to the Kaplan-Mei-
er survival curves. We showed that the above cut-off values 
for both Hb level (p = 0.005) and RDW (p = 0.007) for 
12 months of follow-up stratified our patients into two groups 
with significantly different survival (Figs. 5, 6).
For 24 months of follow-up, the above cut-off for RDW 
was not significant (p = 0.24) for a difference in patient sur-
vival but the cut-off for Hb level was significant (p = 0.017) 
(Figs. 7, 8).
Table 3. Univariate and multivariate analysis. Cox proportional 
hazard model at 1 year of follow-up; bold indicates statistically 
significant values (p < 0.05)
P HR (–95%; 95% CI 
for HR) 
Univariate analysis
NYHA 0.053 0.498 (0.245; 1.01)
LVEF 0.15 0.973 (0.936; 1.01)
Haemoglobin 0.022 0.793 (0.65; 0.967)
MCV 0.394 1.025 (0.968; 1.085)
MCH 0.656 1.029 (0.907; 1.168)
MCHC 0.399 0.897 (0.698; 1.154)
RDW 0.004 1.257 (1.077; 1.467)
Troponin T 0.098 137.09 (0.403; 46618.1)
NT-proBNP < 0.001 1 (1; 1)
Multivariate analysis
RDW 0.044 1.19 (1.004; 1.411)
NT-proBNP 0.008 1 (1; 1)
CI — confidence interval; HR — hazard ratio; LVEF — left ventricular 
ejection fraction; rest abbreviations as in Table 1
Table 4. Univariate and multivariate analysis. Cox proportional 
hazard model at 2 years of follow-up; bold indicates statistically 
significant values (p < 0.05)
P HR (–95%; 95% CI 
for HR)
Univariate analysis
NYHA 0.007 0.379 (0.188; 0.763)
LVEF 0.018 0.956 (0.922; 0.9924)
Haemoglobin 0.066 0.835 (0.689; 1.012)
MCV 0.247 1.033 (0.978; 1.091)
MCH 0.452 1.047 (0.929; 1.181)
MCHC 0.568 0.931 (0.729; 1.189)
RDW 0.044 1.176 (1.005; 1.375)
Troponin T 0.086 145.094 (0.499; 42232.14)
NT-proBNP < 0.001 1 (1; 1)
Multivariate analysis
NT-proBNP 0.006 1 (1; 1)
NYHA 0.024 0.439 (0.215; 0.897)
CI — confidence interval; HR — hazard ratio; LVEF — left ventricular 
ejection fraction; rest abbreviations as in Table 1
Table 5. Comparison of area under the curve (AUC) for haemoglobin (Hb) level and red blood cell distribution width (RDW) versus  
N-terminal pro-B-type natriuretic peptide (NT-proBNP) level for 12 months and 24 months of follow-up
AUC RDW/Hb AUC NT-proBNP Z P r
RDW vs. NT-proBNP — > 12 months 0.63 0.684 0.828 0.408 0.266
RDW vs. NT-proBNP — > 24 months 0.6 0.66 1.038 0.299 0.294
Hb vs. NT-proBNP — > 12 months 0.662 0.684 0.35 0.727 0.288
Hb vs. NT-proBNP — > 24 months 0.581 0.66 1.328 0.184 0.273
DISCUSSION
Studies published in the recent years indicate that increased 
RDW is associated with worse outcomes, e.g. in stable angina, 
peripheral vascular disease, and acute myocardial infarction 
[5–7]. The pathogenesis of RDW changes, iron metabolism 
disturbances, and anaemia in patients with CHF is still debated 
[8–10]. It is currently believed that an increase in RDW and 
associated worse outcomes in patients with CHF are related 
to multiple interrelated pathomechanisms including oxidative 
stress, increased immune system activation, chronic inflam-
mation, abnormal body iron distribution, malnutrition, and 
cachexia [11–15].
Felker et al. [16] were the first to indicate the potential 
of RDW as a simple parameter useful in these patients. This 
study evaluated two patient populations, 2679 participants of 
the CHARM study and 2140 patients from the Duke Databank 
study. In the CHARM study population, in which association of 
36 parameters with the rate of the combined study endpoint 
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(cardiovascular death or admission due to HF) was evaluated, 
RDW was one of the parameters that showed the strongest 
correlation with the rate of the study endpoint. In the other 
patient population, the association between RDW and mortal-
ity was evaluated. RDW was shown to the strongest, excluding 
age, predictor of all-cause mortality [16]. Al-Najjar et al. [17] 
showed that the prognostic values of RDW is comparable to 
that of NT-proBNP level. The need to include RDW when 
stratifying risk in patients with CHF has been also evidenced 
by the studies by Aung et al. [18] and Cauthen et al. [19] 
which indicated that also the dynamics of RDW increase was 
associated with a higher rate of cardiovascular events. 
The prevalence of anaemia in patients with CHF is high, 
ranging from 4% to 55% depending on the studied popula-
tion and the definition of anaemia [20]. The prevalence of 
anaemia in this population is positively correlated with patient 
Figure 1. The receiver operating characteristic curve for red 
blood cell distribution width (RDW) at 12 months of follow-
-up; NT-proBNP — N-terminal pro-B-type natriuretic peptide
Figure 3. The receiver operating characteristic curve for  
haemoglobin (Hb) level at 12 months of follow-up;  
NT-proBNP — N-terminal pro-B-type natriuretic peptide
Figure 2. The receiver operating characteristic curve for red 
blood cell distribution width (RDW) at 24 months of follow-
-up; NT-proBNP — N-terminal pro-B-type natriuretic peptide
Figure 4. The receiver operating characteristic curve for  
haemoglobin (Hb) level at 24 months of follow-up;  
NT-proBNP — N-terminal pro-B-type natriuretic peptide
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age, disease severity as evaluated using the NYHA class, LVEF, 
female gender, chronic kidney disease, and hypertension [9]. 
Many authors confirmed the correlation between anae-
mia and worse outcomes in patients with HF [17–19]. In 
the study by Anand et al. [10] which included 912 patients 
(mean age 62 ± 12 years, LVEF 22 ± 6%, mean Hb level 
13.8 ± 1.6 g/dL), multivariate analysis showed a significant 
effect of anaemia on both the severity of HF symptoms and 
all-cause mortality. Compared to our study, data on the racial 
background of the included patients were not available, and 
the exclusion criteria did not included haemodynamically 
unstable patients, 30% of which were in NYHA class IIIb/IV 
[10]. In the study by Kosiborod et al. [20], medical records 
of 50,405 patients were evaluated. Similarly to our study, 
low Hb level was not shown to be an independent, statisti-
cally significant factor affecting all-cause mortality. Despite 
similar findings, the population studied by Kosiborod et al. 
[20] was significantly older (mean age 79.4 ± 0.05 years, 
patients < 65 years of age were included), with 84.44% of 
Caucasians, and haemodynamically unstable patient condition 
was not an exclusion criterion.
Our study is one of the first Polish publications on the 
prognostic value of RDW in patients with CHF and the first 
one to evaluate it prospectively over 2 years of follow-up. Our 
findings confirm few previous reports indicating that RDW 
may be a significant predictor of mortality in patients with 
CHF during 1-year follow-up. Haemoglobin level was not 
an independent prognostic factor and only a co-predictor of 
mortality during 1-year follow-up. Other red blood cell param-
eters evaluated in our study, i.e. MCV, MCH and MCHC, were 
Figure 5. The Kaplan-Meier survival curve for red blood cell 
distribution width (RDW) stratified using the proposed cut-off 
value for 12 months of follow-up
Figure 7. The Kaplan-Meier survival curve for red blood cell 
distribution width (RDW) stratified using the proposed cut-off 
value for 24 months of follow-up
Figure 6. The Kaplan-Meier survival curve for haemoglobin 
level stratified using the proposed cut-off value for 12 months 
of follow-up
Figure 8. The Kaplan-Meier survival curve for haemoglobin 
level stratified using the proposed cut-off value for 24 months 
of follow-up
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not found to be useful predictors of mortality in patients with 
CHF. The prognostic importance of RDW as an independent 
predictor of mortality appears to lose its statistical significance 
over longer-term follow-up. This finding may be related to 
the fact that during long-term follow-up, the only significant 
parameters are those clearly related to worse haemodynamics.
Limitations of the study
The findings of our study may not be applied to patients with 
decompensated systolic CHF, acute HF, and HF with preserved 
left ventricular function. 
CONCLUSIONS
Baseline RDW and Hb level in patients hospitalised with the 
diagnosis of NYHA class II–IV CHF seem to be important pre-
dictors of mortality in this population. Among the red blood 
cell parameters, only RDW was shown to be an independent 
prognostic factor at 1 year of follow-up but it appeared to lose 
its significance during longer-term follow-up. These findings 
should be confirmed in multicentre studies in ethnically and 
culturally diverse populations of patients at various age. As-
sessment of baseline Hb level in patients hospitalised with 
the diagnosis of NYHA class II–IV CHF seems to be useful for 
stratification of mortality risk in this patient group.
Conflict of interest: none declared
References
1. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and 
morbidity in patients with chronic heart failure. Eur Heart J, 
2006; 27: 65–75. doi: 10.1093/eurheartj/ehi555.
2. Oleszczyk K, Zielińska-Meus A, Pacholewicz J et al. Drugi etap 
rehabilitacji chorych z mechanicznym wspomaganiem lewej 
komory serca typu HeartWare. Kardiochir Torakochir Pol, 2010; 
7: 188–190. 
3. Velavan P, Khan NK, Goode K et al. Predictors of short term mor-
tality in heart failure: insights from the Euro Heart Failure survey. 
Int J Cardiol, 2010; 138: 63–69. doi: 10.1016/j.ijcard.2008.08.004.
4. Massie BM, Shah NB. The heart failure epidemic: magnitude of the 
problem and potential mitigating approaches. Curr Opin Cardiol, 
1996; 11: 221–226. doi: 10.1097/00001573-199605000-00001.
5. Ye Z,  Smith C, Kullo IJ. Usefulness of red cell distribution 
width to predict mortality in patients with peripheral artery 
disease. Am J Cardiol, 2011; 107: 1241–1245. doi: 10.1016/j.
amjcard.2010.12.023.
6. Tonelli M, Sacks F, Arnold M et al. Relation between red blood 
cell distribution width and cardiovascular event rate in people 
with coronary disease. Circulation, 2008; 117: 163–168. doi: 
10.1161/CIRCULATIONAHA.107.727545.
7. Dabbah S, Hammerman H, Markiewicz W, Aronson D. Rela-
tion between red cell distribution width and clinical outcomes 
after acute myocardial infarction. Am J Cardiol, 2010; 105: 
312–327. doi: 10.1016/j.amjcard.2009.09.027.
8. Jankowska E, Malyszko J, Ardehali H et al. Iron status in patients 
with chronic heart failure. Eur Heart J, 2013; 34: 827–834. doi: 
10.1093/eurheartj/ehs377.
9. Ezekowitz JA, Mc Alister FA, Armstrong PW. Anemia is com-
mon in heart failure and is associated with poor outcomes: 
insights from a cohort of 12 065 patients with new-onset heart 
failure. Circulation, 2003; 107: 223–225. doi: 10.1161/01.
CIR.0000052622.51963.FC.
10. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relation-
ship to clinical outcome in heart failure. Circulation, 2004; 110: 
149–154. doi: 10.1161/01.CIR.0000134279.79571.73.
11. Förhécz Z, Gombos T, Borgulya G et al. Red cell distribution 
width in heart failure: prediction of clinical events and rela-
tionship with markers of ineffective erythropoiesis, inflamma-
tion, renal function, and nutritional state. Am Heart J, 2009; 4: 
659–666. doi: 10.1016/j.ahj.2009.07.024.
12. Lippi G, Targher G, Montagnana M et al. Relationship between 
red blood cell distribution width and kidney function tests in 
a large cohort of unselected outpatients. Scand J Clin Lab Invest, 
2008; 8: 745–748. doi: 10.1080/00365510802213550.
13. Lippi G, Targher G, Montagnana M et al. Relation between red 
blood cell distribution width and inflammatory biomarkers in 
a large cohort of unselected outpatients. Arch Pathol Lab Med, 
2009; 628–632. doi: 10.1043/1543-2165-133.4.628.
14. Montagnana M, Cervellin G, Meschi T, Lippi G. The role of 
red blood cell distribution width in cardiovascular and throm-
botic disorders. Clin Chem Lab Med, 2012; 4: 635–641. doi: 
10.1515/cclm.2011.831.
15. Allen LA, Felker GM, Mehra MR et al. Validation and potential 
mechanisms of red cell distribution width as a prognostic marker 
in heart failure. J Card Fail, 2010; 230–238. doi: 10.1016/j.card-
fail.2009.11.003.
16. Felker GM, Allen LA, Pocock SJ et al. Red cell distribution width 
as a novel prognostic marker in heart failure: data from the 
CHARM Program and the Duke Databank. J Am Coll Cardiol, 
2007; 50: 40–47. doi: 10.1016/j.jacc.2007.02.067.
17. Al-Najjar Y, Goode KM, Zhang J et al. Red cell distribution 
width: an inexpensive and powerful prognostic marker in heart 
failure. Eur J Heart Fail, 2009; 11: 1155–1162. doi: 10.1093/eur-
jhf/hfp147.
18. Aung N, Ling HZ, Cheng AS et al. Expansion of the red cell 
distribution width and evolving iron deficiency as predictors of 
poor outcome in chronic heart failure. Int J Cardiol, 2013; 168: 
1997–2002. doi: 10.1016/j.ijcard.2012.12.091.
19. Cauthen CA, Tong W, Jain A, Tang WH. Progressive rise in red 
cell distribution width is associated with disease progression in 
ambulatory patients with chronic heart failure. J Card Fail, 2013; 
18: 146–152. doi: 10.1016/j.cardfail.2011.10.013.
20. Kosiborod M, Curtis JP, Wang Y et al. Anemia and Outcomes 
in Patients With Heart Failure. Arch Intern Med, 2005; 165: 
2237–2244. doi: 10.1001/archinte.165.19.2237.
www.kardiologiapolska.pl664
Adres do korespondencji: 
lek. Łukasz P. Wołowiec, Studenckie Koło Naukowe Diagnostyki i Terapii Niewydolności Serca, II Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja 
Kopernika w Toruniu, Szpital Uniwersytecki nr 2 im. dr. Jana Biziela, ul. Ujejskiego 75, 85–168 Bydgoszcz, e-mail: lordtor111@gmail.com 
Praca wpłynęła: 18.06.2015 r. Zaakceptowana do druku: 15.12.2015 r. Data publikacji AoP: 07.01.2016 r.
Znaczenie rokownicze rozpiętości rozkładu 
objętości erytrocytów i innych parametrów  
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S t r e s z c z e n i e
Wstęp: Badania opublikowane w ciągu ostatniej dekady zdają się wskazywać na parametry czerwonokrwinkowe jako tanie, szybkie i proste 
narzędzia do określania rokowania pacjentów z przewlekłą niewydolnością serca (CHF). Poznanie dokładnego związku patofizjologicznego 
między zmianami wartości parametrów czerownokrwinkowych a CHF może dać wiele nowych możliwości terapeutycznych u pacjentów z CHF. 
Cel: Celem pracy była ocena wartości rokowniczej rozpiętości rozkładu objętości erytrocytów (RDW) i pozostałych parametrów czerwo-
nokrwinkowych oznaczanych w rutynowej morfologii krwi obwodowej podczas 2-letniej obserwacji, w grupie pacjentów z CHF, a także 
porównanie tej wartości z wartością rokowniczą tych parametrów w przypadku rocznego okresu obserwacji.
Metody: Grupę badaną stanowiło 165 pacjentów hospitalizowanych w II Klinice Kardiologii Collegium Medicum Uniwersytetu Mikołaja 
Kopernika z CHF w II–IV klasie wg New York Heart Association (NYHA). U wszystkich pacjentów z grupy badanej w pierwszym dniu hospi-
talizacji wykonano morfologię krwi obwodowej z oceną stężenia hemoglobiny, średniej objętości krwinki czerwonej (MCV), średniej masy 
hemoglobiny w krwince czerwonej (MCH), średniego stężenia hemoglobiny w objętości krwinek czerwonych (MCHC) oraz RDW. Obser-
wację pacjentów, która trwała łącznie 24 miesiące, prowadzono telefonicznie, co 3 miesiące od momentu włączenia pacjenta do badania. 
Punktem końcowym była śmiertelność ogólna.
Wyniki: Analizie poddano 165 pacjentów (mężczyźni: 83%, średni wiek: 60 ± 13 lat). W trakcie 24-miesięcznej obserwacji zmarło 47 (28,5%) 
pacjentów. Spośród parametrów czerwonokrwinkowych MCV, MCH i MCHC nie okazały się wartościowymi predyktorami zgonów w grupie 
chorych z CHF zarówno w 1-rocznym, jak i 2-letnim okresie obserwacji. W analizie jednoczynnikowej dla 1-rocznego okresu obserwacji 
stwierdzono istotny statystycznie wpływ następujących parametrów na wystąpienie punktu końcowego: hemoglobina (p = 0,022; HR = 0,80), 
RDW (p = 0,004; HR = 1,257), N-końcowy propeptyd natriuretyczny typu B (NT-proBNP; p = 0,0001; HR = 1), analiza wieloczynniko-
wa dla rocznego okresu obserwacji wykazała, że RDW i NT-proBNP są niezależnymi, istotnymi statystycznie czynnikami wpływającymi na 
wystąpienie zgonu. Analiza jednoczynnikowa dla 2-letniego okresu obserwacji wykazała istotny statystycznie wpływ na wystąpienie punktu 
końcowego następujących parametrów: frakcja wyrzutowa (p = 0,018; HR = 0,956), klasa NYHA (p = 0,007; HR = 0,378), RDW (p = 0,044; 
HR = 1,175), NT-proBNP (p < 0,001; HR = 1), natomiast analiza wieloczynnikowa 2-letniego okresu obserwacji wykazała, że NT-proBNP 
(p = 0,006; HR = 1) i klasa NYHA (p = 0,024; HR = 0,439) są niezależnymi, istotnymi statystycznie czynnikami wpływającymi na wystą-
pienie zgonu. Proponowany punkt odcięcia dla RDW w obserwacji 12-miesięcznej wyniósł 15,00% (AUC = 0,63; 0,523–0,737), natomiast 
dla okresu 24 miesięcy — 14,00% (AUC = 0,6; 0,504–0,697). W przypadku hemoglobiny proponowany punkt odcięcia w obserwacji 
12-miesięcznej wyniósł 13,9 g/dl (AUC = 0.662; 0,553–0,77), natomiast dla okresu 24 miesięcy — 12,2 g/dl (AUC = 0.581; 0,482–0,681). 
Wnioski: Oznaczane przy przyjęciu RDW i stężenie hemoglobiny u chorych hospitalizowanych z rozpoznaniem CHF w II–IV klasie wg NYHA 
wydają się istotnymi czynnikami rokowniczym wystąpienia zgonu w tej populacji pacjentów. Spośród parametrów czerwonokrwinkowych 
jedynie RDW okazał się niezależnym czynnikiem rokowniczym dla 1-rocznego okresu obserwacji, jednak jego znaczenie rokownicze zanika 
w obserwacji długoterminowej.
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